- Home
- JGH vs VNDA Comparison
JGH vs VNDA Comparison
Compare JGH & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JGH
- VNDA
- Stock Information
- Founded
- JGH 2014
- VNDA 2002
- Country
- JGH United States
- VNDA United States
- Employees
- JGH N/A
- VNDA N/A
- Industry
- JGH Investment Managers
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- JGH Finance
- VNDA Health Care
- Exchange
- JGH Nasdaq
- VNDA Nasdaq
- Market Cap
- JGH 292.3M
- VNDA 275.2M
- IPO Year
- JGH N/A
- VNDA 2006
- Fundamental
- Price
- JGH $13.23
- VNDA $4.19
- Analyst Decision
- JGH
- VNDA Strong Buy
- Analyst Count
- JGH 0
- VNDA 3
- Target Price
- JGH N/A
- VNDA $15.33
- AVG Volume (30 Days)
- JGH 73.9K
- VNDA 559.3K
- Earning Date
- JGH 01-01-0001
- VNDA 07-31-2025
- Dividend Yield
- JGH 9.85%
- VNDA N/A
- EPS Growth
- JGH N/A
- VNDA N/A
- EPS
- JGH N/A
- VNDA N/A
- Revenue
- JGH N/A
- VNDA $203,467,000.00
- Revenue This Year
- JGH N/A
- VNDA $16.86
- Revenue Next Year
- JGH N/A
- VNDA $39.78
- P/E Ratio
- JGH N/A
- VNDA N/A
- Revenue Growth
- JGH N/A
- VNDA 3.18
- 52 Week Low
- JGH $10.36
- VNDA $3.81
- 52 Week High
- JGH $12.85
- VNDA $5.97
- Technical
- Relative Strength Index (RSI)
- JGH 67.45
- VNDA 32.22
- Support Level
- JGH $12.89
- VNDA $4.60
- Resistance Level
- JGH $13.25
- VNDA $4.89
- Average True Range (ATR)
- JGH 0.10
- VNDA 0.17
- MACD
- JGH 0.01
- VNDA -0.07
- Stochastic Oscillator
- JGH 94.44
- VNDA 3.66
About JGH Nuveen Global High Income Fund of Beneficial Interest
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of current income. Its securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.